SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
SEPTEMBER 9, 2002
-----------------
CUBIST PHARMACEUTICALS, INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-21379 22-3192085
- -------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
65 HAYDEN AVENUE, LEXINGTON, MASSACHUSETTS 02421
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (781) 860-8660
--------------
ITEM 5. OTHER EVENTS.
On September 9, 2002, the Registrant and Gilead Sciences issued a joint
press release announcing the termination of their licensing agreement for the
commercialization of Cidecin (daptomycin for injection) and an oral formulation
of daptomycin. The press release has been filed as an exhibit to this Report on
Form 8-K, attached hereto as Exhibit 99.1.
In addition, the joint press release also announced that the
Registrant will host a conference call and live webcast. Information relating
to the conference call is as follows:
When: Monday September 9, 2002 at 5:00 pm ET
Domestic and Canada Call-in: (800) 915-4836
International Call-in: (973) 317-5319
Call will be webcast live, listen only, at:
http://www.vcall.com/EventPage.asp?ID=82290
A replay of the conference call will be available for thirty days via the
internet.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS.
99.1 Press Release dated September 9, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CUBIST PHARMACEUTICALS, INC.
By: /s/ Thomas A. Shea
--------------------------------
Thomas A. Shea
Vice President Finance and
Administration, Chief Financial
Officer, Treasurer
Dated: September 9, 2002